TheraRadar
← Back
Data updated: Jun 28, 2026

UDL

Generics
Pharmaceuticals

UDL is a generic drug manufacturer with 4 FDA-approved products.

1983
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

UDL's Key Drugs

UDL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

UDL's Recent FDA Approvals

New NDA/BLA approvals for UDL over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

UDL's Therapeutic Areas

Disease areas where UDL has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

UDL Pipeline Snapshot

Active clinical trials for UDL across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling